Toxicity and relative dose intensity (RDI) of FOLFOX 6 chemotherapy in patients of differing body mass index treated for colorectal cancerBackground Colorectal cancer is the third leading cause of death from cancer worldwide. It has been suggested that obesity may be a promoting factor in the ...
Standard treatment for patients with HER2-negative, metastatic gastric/GEJ adenocarcinoma is chemotherapy with mFOLFOX6, but there is still an unmet need in terms of targeted therapies for this population.2Currently, the median OS is approximately 1 year. CLDN18.2 is a tight jun...